SCHEMBL3548150

SCHEMBL3548150

CC(C)CN1CCC(=O)N(C)c2cnc(Cl)nc21

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 2/20 0.37
PIK3CD O00329 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
RAD52 P43351 1/20 0.32
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
HSP90AA1 P07900 2/20 0.31
HSP90AB1 P08238 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TTK P33981 2/20 0.31
PLK1 P53350 2/20 0.31
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543954 0.89 RPS6KA3 (0.45) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3543105 0.84 SMN1; SMN2 (0.38) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3543738 0.82 SMN1; SMN2 (0.35) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3668641 0.82 ALDH1A1 (0.35) RPS6KA3SMN1; SMN2NPC1RAB9ACYP11B1
SCHEMBL3543713 0.81 RAD52 (0.38) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3542695 0.81 KDM4E (0.37) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3539514 0.81 SMN1; SMN2 (0.34) RPS6KA3SMN1; SMN2CYP11B1CYP11B2RAD52
SCHEMBL3543190 0.81 TRPC5 (0.36) SMN1; SMN2CYP11B1CYP11B2RAD52TTK
SCHEMBL3542245 0.81 SMN1; SMN2 (0.37) RPS6KA3SMN1; SMN2CYP11B1CYP11B2ABL1
SCHEMBL3543108 0.81 DRD2 (0.36) SMN1; SMN2RAD52HSP90AA1HSP90AB1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709471-B2 Compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-2046793-A2 FUSED PYRIMIDO COMPOUNDS AstraZeneca AB (SE) 2009-04-15 EP disclosed
WO-2008003958-A2 FUSED PYRIMIDO COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
US-20080009482-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009482-A1 NOVEL COMPOUNDS CYP11B2, CYP11B1, CYP46A1 RPS6KA3 248/4885PIK3CD 2632/4885SMN1; SMN2 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.